Examining the epidemiological studies that have established a connection between regular genital talcum powder use and an increased risk of ovarian cancer — and why courts around the world have sided with claimants.
Ovarian Cancer in the UK
Ovarian cancer is the sixth most common cancer in women in the UK, with around 7,500 new cases diagnosed each year. The disease is often diagnosed late because symptoms can be vague and may be mistaken for other conditions. While multiple risk factors exist, research has increasingly focused on talcum powder use as a modifiable risk factor that women can control.
Decades of Research
Research into talc and ovarian cancer dates back to the 1970s, with Daniel Cramer at Harvard publishing a landmark study in 1982 showing a clear association between talcum powder use and ovarian cancer risk. Multiple subsequent studies confirmed this finding across different populations and methodologies. A 2018 meta-analysis of 27 studies found a statistically significant association between perineal talc use and ovarian cancer, with women who regularly used talc in the genital area showing an increased risk of epithelial ovarian cancer, particularly the serous and endometrioid subtypes.
How Talc May Cause Ovarian Cancer
The biological mechanism is well understood. Talc particles applied to the genital area can migrate through the reproductive tract to the ovaries, where they have been found embedded in ovarian tissue. The chronic inflammation caused by these foreign particles may trigger cellular changes leading to cancer development. Where talc is contaminated with asbestos, a known carcinogen, the risk is compounded significantly. This biological plausibility strengthens the epidemiological evidence and provides a clear mechanism by which talcum powder exposure could cause ovarian cancer.
What Courts Have Found
Courts around the world have increasingly sided with claimants. In 2018, a Missouri jury awarded $4.69 billion to 22 women in a landmark case, though this was later reduced on appeal. In December 2025, Los Angeles awarded a $40 million verdict for two women with ovarian cancer, and in February 2026, a Philadelphia jury delivered a significant verdict for the family of a deceased ovarian cancer victim. Johnson & Johnson now faces over 90,000 lawsuits, the majority involving ovarian cancer claims. Importantly, courts have consistently found the scientific evidence sufficient to establish causation between talcum powder use and ovarian cancer.
The UK Group Action
Jones Whyte is pursuing claims in the Scottish Court of Session on behalf of women diagnosed with ovarian cancer after talc use. The group action includes claims for deceased individuals — family members can pursue claims on their behalf if a loved one has passed away from ovarian cancer. The representative claimant, Helene Rose, was diagnosed with Stage 4 ovarian cancer in 2024. The claimants allege that Johnson & Johnson knew about contamination risks and potential health hazards based on internal company documents dating back to the 1960s, which they failed to disclose to consumers.
If You Are Affected
If you have a diagnosis of ovarian cancer and a history of talcum powder use, it is important to seek legal advice promptly. Limitation periods apply in Scotland, meaning there are time restrictions on when claims can be brought. The good news is that Jones Whyte offers no win, no fee representation, meaning you will not pay legal costs unless your claim is successful. Early investigation also preserves evidence and strengthens your claim.
This article is for general information only and does not constitute legal advice.